A randomized, open, three-period crossover study to compare the pharmacokinetic profile of paroxetine after single dosing of each enteric-coated geomatrix control release tablet strength (12.5, 25, 37.5mg) in healthy Chinese subjects

Trial Profile

A randomized, open, three-period crossover study to compare the pharmacokinetic profile of paroxetine after single dosing of each enteric-coated geomatrix control release tablet strength (12.5, 25, 37.5mg) in healthy Chinese subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Paroxetine (Primary)
  • Indications Depressive disorders; Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Post-traumatic stress disorders; Premenstrual dysphoric disorder; Social phobia
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 20 Apr 2008 Status changed from in progress to completed.
    • 07 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top